iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL.

@article{Hallek2018iwCLLGF,
  title={iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL.},
  author={Michael Hallek and Bruce D Cheson and Daniel Catovsky and Federico caligaris-Cappio and Guillermo Dighiero and Hartmut D{\"o}hner and Peter Hillmen and Michael J. Keating and Emili Montserrat and Nicholas Chiorazzi and Stephan Stilgenbauer and Kanti R. Rai and John C. Byrd and Barbara F. Eichhorst and Susan O'brien and Tadeusz Robak and John Francis Seymour and Thomas J. Kipps},
  journal={Blood},
  year={2018},
  volume={131 25},
  pages={
          2745-2760
        }
}
The previous edition of the consensus guidelines of the International Workshop on Chronic Lymphocytic Leukemia (iwCLL), published in 2008, has found broad acceptance by physicians and investigators caring for patients with CLL. Recent advances including the discovery of the genomic landscape of the disease, the development of genetic tests with prognostic relevance, and the detection of minimal residual disease (MRD), coupled with the increased availability of novel targeted agents with… 

Tables from this paper

Guidelines for Diagnosis, Indications for Treatment, Response Assessment, and Supportive Management of Chronic Lymphocytic Leukemia: The 2018 Update
TLDR
These guidelines were recently published and include a revised version of the iwCLL response criteria, an update on the use of the MRD status in the clinical context, and recommendations regarding the assessment and prophylaxis of viral diseases during the management of CLL.
Diagnosis and Treatment of Chronic Lymphocytic Leukemia: Recommendations of the French CLL Study Group (FILO)
TLDR
The recommendations of the French Innovative Leukemia Organization (FILO-CLL) group presented here are intended to provide practical recommendations for physicians taking care of CLL patients, taking into account the availability of both biological tests and therapies in daily practice in France at the time of publication.
Treatment-naive CLL: lessons from phase 2 and phase 3 clinical trials.
TLDR
The management of previously untreated CLL is discussed with an emphasis on the clinical trials that have formed the standard of care, as well as those newer studies that are likely to form the next generation of therapy.
Treatment-naive CLL: lessons from phase 2 and phase 3 clinical trials.
  • J. Woyach
  • Medicine
    Hematology. American Society of Hematology. Education Program
  • 2019
TLDR
The management of previously untreated CLL is discussed with an emphasis on the clinical trials that have formed the standard of care, as well as those newer studies that are likely to form the next generation of therapy.
Management of Chronic Lymphocytic Leukemia in Less-Resourced Countries.
TLDR
Issues regarding management of CLL in some less-resourced countries are reviewed, with a focus on the evidence basis for epidemiological and clinical information on this disease, the availability of diagnostic and therapeutic resources, and participation in clinical trials.
Acalabrutinib in management of chronic lymphocytic leukemia: An Indian perspective
TLDR
The aim of this review article is to gather results from all landmark CLL trials and discuss the feasibility of incorporating Acalabrutinib in the CLL landscape from an Indian perspective.
Early intervention in asymptomatic chronic lymphocytic leukemia.
TLDR
Recommendations are based on decades of careful observations showing that treatment in early-stage CLL does not improve overall survival and the time is ripe to re-examine this question.
The Evolving Landscape of Chronic Lymphocytic Leukemia on Diagnosis, Prognosis and Treatment
TLDR
There has been an impressive explosion of new approaches based on targeted therapies for CLL patients during the last decade, and next-generation sequencing identified an unprecedented number of gene mutations with potential prognostic and predictive value.
...
...

References

SHOWING 1-10 OF 145 REFERENCES
Novel targeted agents and the need to refine clinical end points in chronic lymphocytic leukemia.
  • B. Cheson, J. Byrd, T. Kipps
  • Medicine, Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2012
Standardized criteria for response to therapy in patients with chronic lymphocytic leukemia (CLL), lymphoma, and other malignancies allow for comparisons of outcome between clinical trials and have
The role of minimal residual disease measurements in the therapy for CLL: is it ready for prime time?
Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines.
TLDR
The International Workshop on Chronic Lymphocytic Leukemia (IWCLL) to provide updated recommendations for the management of CLL in clinical trials and general practice is provided.
Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update.
TLDR
Current recommendations for the management of patients exposed to lethal doses of total-body radiotherapy, but not doses high enough to lead to certain death as a result of injury to other organs, include the prompt administration of CSFs.
Updated guidelines on the management of cytomegalovirus reactivation in patients with chronic lymphocytic leukemia treated with alemtuzumab.
TLDR
Several strategies for monitoring and treating CMV reactivation in patients with CLL receiving alemtuzumab-based therapy are discussed and practical recommendations for CMV management are provided by building upon the guidelines published previously in 2004.
ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia—update on methodological approaches and results interpretation
TLDR
Advice is offered to ensure that the analysis is performed in a timely manner for all patients requiring treatment and that the data is interpreted and reported in a consistent, standardized, and accurate way and next-generation sequencing technologies are gaining prominence within diagnostic laboratories.
Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia.
TLDR
The majority of very low-risk patients remained free of progression after treatment and their hazard of relapse decreased after 4 years from FCR, indicating that neither the disease nor complications of its treatment affected survival in this favorable CLL group.
Prognostic factors in chronic lymphocytic leukemia—what do we need to know?
TLDR
This Review provides a concise discussion of the most important discoveries and gives guidance on how to implement novel prognostic tools in the clinical management of CLL by applying the criteria of evidence, relevance, and simplicity to the selection of prognostic markers.
Challenges in the Role of Gammaglobulin Replacement Therapy and Vaccination Strategies for Hematological Malignancy
TLDR
The need for assessing and monitoring specific antibody responses is re-emphasized to select adequately those patients for whom early intervention with prophylactic anti-infective therapy and/or IVIg is preferred.
Guidelines for clinical protocols for chronic lymphocytic leukemia: Recommendations of the national cancer institute‐sponsored working group
TLDR
The National Cancer Institute‐sponsored Chronic Lymphocytic Leukemia (CLL) Working Group was convened to develop a set of standardized eligibility, response, and toxicity criteria for clinical trials, and the emergence of several chemotherapy agents that promise impressive activity in CLL is witnessed.
...
...